New Lawsuit Says Maker of Fertility Drug Bravelle Hid Potency Issues From Doctors, Public

TRENTON, N.J. — A new lawsuit accuses Ferring Pharmaceuticals Inc. of hiding potency and stability problems with its fertility drug Bravelle, and of taking shortcuts in its manufacture in order to cut costs and boost sales.

Seven plaintiffs filed the Oct. 5 complaint in the U.S. District Court for the District of New Jersey, alleging that before ultimately recalling Bravelle in 2015, Ferring was or should have been on heightened notice of the drug’s potential stability and potency issues.

Bravelle is an injectable follicle-stimulating hormone (FSH) used in conjunction with in vitro fertilization — an assisted reproductive technology (ART) — …